However, Bezin J. et al. recently published a study on 2562 case subjects that showed an increased risk of all thyroid cancers (adjusted HR 1.58, 95% CI 1.27–1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04–3.5) after 1–3 years of GLP-1 RA use [78]. This evidence concerns the gene GLP1R and medullary thyroid gland carcinoma.